ADZYNMA Purple Book BLA 125795
- BLA number
- 125795
- Proprietary names
- ADZYNMA
- Proper names
- ADAMTS13, recombinant-krhn
- Applicant
- Takeda Pharmaceuticals U.S.A., Inc.
- Center
- CBER
- First observed release
- 2023-11-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | ADZYNMA | ADAMTS13, recombinant-krhn | 351(a) | 500IU | For Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2023-11-09 | |
| 002 | ADZYNMA | ADAMTS13, recombinant-krhn | 351(a) | 1500IU | For Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2023-11-09 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2024-01-01 | U | 001 | ADZYNMA | 351(a) | Rx | Takeda Pharmaceuticals U.S.A., Inc. |
| 2024-01-01 | U | 002 | ADZYNMA | 351(a) | Rx | Takeda Pharmaceuticals U.S.A., Inc. |
| 2023-11-01 | U | 001 | ADZYNMA | 351(a) | Rx | Takeda Pharmaceuticals U.S.A., Inc. |
| 2023-11-01 | U | 002 | ADZYNMA | 351(a) | Rx | Takeda Pharmaceuticals U.S.A., Inc. |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2023-11-01 | 001 | ADZYNMA | 351(a) | Rx | Licensed | 2023-11-09 |
| 2023-11-01 | 002 | ADZYNMA | 351(a) | Rx | Licensed | 2023-11-09 |